Neoleukin Therapeutics Investor Relations Material
Latest events
M&A Announcement
Neoleukin Therapeutics
Q4 2023
18 Mar, 2024
Q2 2023
10 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Neoleukin Therapeutics Inc
Access all reports
Neoleukin Therapeutics Inc. is a biopharmaceutical company focused on developing immunotherapies using its proprietary de novo protein design technology. The company’s approach involves creating novel proteins to target immune system pathways, with a particular focus on cancer and inflammatory diseases. Neoleukin’s therapies aim to harness and modulate the immune system to treat diseases more effectively. The company is headquartered in Seattle, Washington, and its shares are listed on the NASDAQ.
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
NLTX
Country
🇺🇸 United States